Renaissance has announced a strategic partnership with CyberSmart, a UK-based cybersecurity provider focused on delivering continuous protection, compliance, and cyber risk management for small and medium-sized enterprises (SMEs).

Signaloid previews a new ASIC purpose-built for physical AI and robotics workloads.

CPI Enterprises, part of the High Value Manufacturing Catapult, has invested £500,000 in Cambridge-based life sciences company Verinnogen to support the development of a novel technology designed to improve the accuracy and reliability of cancer drug development.

Kiril Kirov from Qureight discusses how synthetic control arms offer an alternative to conventional control groups and improve clinical trial design.

Ambient-temperature preservation solution enables reliable storage and shipment of organoids and spheroids, to support growing adoption of New Approach Methodologies.

The NHS is one of the world’s most ambitious public health systems, but it faces mounting pressures from an ageing population, chronic illnesses, and limited public funding.

Cutting-edge sound technology has laid bare a stark contrast in bird life between conventional and regenerative farming in just six days.

Healx, a leading UK artificial intelligence-powered biotech company, continues to reshape drug discovery for rare diseases in 2026, leveraging advanced machine learning to accelerate treatments for conditions that affect millions but often lack approved therapies.

Patients Know Best has collaborated with Heartfelt Technologies to automate and accelerate clinical trial recruitment, by taking a digital-first approach to patients.

A University of Bristol spin-out which has developed an innovative temperature-responsive coating for greenhouses and buildings has been awarded its first UK patent.

Bioprocessing leader to drive continued commercial development and international expansion.

Monument Therapeutics, a stratified medicine company, today announced that the first patient has been dosed in its proof-of-principle clinical trial with MT1988 in patients at clinical high risk (CHR) for psychosis.